Amylyx to present Phase 3 LUCIDITY topline data for avexitide in post-bariatric hypoglycemia at ObesityWeek 2026
AMLX•Amylyx scheduled its Phase 3 LUCIDITY topline data for presentation in a late-breaking oral session on Nov. 15, 2026, in Washington, D.C. Management previously disclosed positive topline results.
1. Presentation scheduled
Amylyx scheduled Phase 3 LUCIDITY topline data for avexitide in post-bariatric hypoglycemia for a late-breaking oral session at ObesityWeek 2026 on Nov. 15 in Washington, D.C. The data had not yet been presented.
2. Earlier results
Management previously disclosed positive topline results, supporting avexitide’s efficacy and safety profile in the pivotal trial. Avexitide targets the GLP-1 pathway to curb inappropriate insulin release and aims to stabilize blood sugar.
